RxDoctor Payments Data

Joseph Tasch, DO

Nephrology · Lancaster, OHNPI 1720462807

Payments from drug & device makers

$452in general payments, 2019–2025

Across 18 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$118
  • Boehringer Ingelheim$116
  • Akebia Therapeutics Inc$34
  • AMAG Pharmaceuticals, Inc.$33
  • Daiichi Sankyo Inc.$32
  • Otsuka America Pharmaceutical, Inc.$30
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$41993%
  • Education$327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$452 in reported general payments places this provider in the 30th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$128,973
Medicare patients
353
Services billed
1,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$23,911
VelphoroSucroferric Oxyhydroxide11$23,599
FarxigaDapagliflozin Propanediol19$18,284
Cinacalcet Hcl18$15,222
LokelmaSodium Zirconium Cyclosilicate11$7,486
Calcitriol223$4,594
Sevelamer Carbonate12$3,367
Valsartan56$2,235
Eplerenone17$2,222
Allopurinol231$2,177
Losartan Potassium234$2,064
Spironolactone274$1,905
Spironolactone-HctzSpironolact/Hydrochlorothiazid57$1,773
Potassium Citrate ErPotassium Citrate15$1,670
Tamsulosin Hcl64$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$15$25,77030 claims
Boehringer IngelheimJardiance$116$23,91126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 nephrology providers in Ohio.

Other nephrology in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →